Colorectal Cancer Forecast and Market Analysis to 2036

CONTENTS

16 FORECAST: COLORECTAL CANCER (Published on 11 December 2017)
16 OVERVIEW
17 EXECUTIVE SUMMARY
18 RECENT FORECAST UPDATES
19 MARKET DYNAMICS
26 FORECAST AND FUTURE TRENDS
37 MARKET DEFINITION AND METHODOLOGY
45 PRIMARY RESEARCH METHODOLOGY
48 BIBLIOGRAPHY
53 PRODUCT PROFILE: AVASTIN
70 PRODUCT PROFILE (LATE STAGE): COTELLIC
84 PRODUCT PROFILE: CYRAMZA
98 PRODUCT PROFILE: ERBITUX
114 PRODUCT PROFILE: KEYTRUDA
129 PRODUCT PROFILE: LONSURF
143 PRODUCT PROFILE (LATE STAGE): ONCOVAX
154 PRODUCT PROFILE: OPDIVO
168 PRODUCT PROFILE: STIVARGA
184 PRODUCT PROFILE: TS-1
194 PRODUCT PROFILE (LATE STAGE): TECENTRIQ
208 PRODUCT PROFILE: VECTIBIX
227 PRODUCT PROFILE: ZALTRAP
239 PRODUCT PROFILE (LATE STAGE): BINIMETINIB
252 PRODUCT PROFILE (LATE STAGE): LEFITOLIMOD
266 PRODUCT PROFILE (LATE STAGE): MASITINIB
280 PRODUCT PROFILE (LATE STAGE): NAPABUCASIN

294 TREATMENT: COLORECTAL CANCER (Published on 25 August 2017)
294 OVERVIEW
295 EXECUTIVE SUMMARY
296 PRIMARY RESEARCH METHODOLOGY
298 DISEASE DEFINITION AND DIAGNOSIS
306 PATIENT SEGMENTATION
308 CURRENT TREATMENT OPTIONS
312 PRESCRIBING TRENDS

332 EPIDEMIOLOGY: COLORECTAL CANCER (Published on 06 September 2018)
332 OVERVIEW
333 DISEASE BACKGROUND
336 METHODOLOGY
352 FORECAST
357 BIBLIOGRAPHY
362 APPENDIX

365 MARKETED DRUGS: COLORECTAL CANCER (Published on 11 December 2017)
365 OVERVIEW
366 EXECUTIVE SUMMARY
367 PRODUCT OVERVIEW
370 PRODUCT PROFILE: AVASTIN
387 PRODUCT PROFILE: CYRAMZA
401 PRODUCT PROFILE: ERBITUX
417 PRODUCT PROFILE: KEYTRUDA
432 PRODUCT PROFILE: LONSURF
446 PRODUCT PROFILE: OPDIVO
460 PRODUCT PROFILE: STIVARGA
476 PRODUCT PROFILE: TS-1
486 PRODUCT PROFILE: VECTIBIX
505 PRODUCT PROFILE: ZALTRAP

517 PIPELINE: COLORECTAL CANCER (Published on 11 December 2017)
517 OVERVIEW
518 EXECUTIVE SUMMARY
519 CLINICAL PIPELINE OVERVIEW
521 ADDITIONAL PHARMA INTELLIGENCE PIPELINE RESOURCES
522 PRODUCT PROFILE (LATE STAGE): COTELLIC
536 PRODUCT PROFILE (LATE STAGE): ONCOVAX
547 PRODUCT PROFILE (LATE STAGE): TECENTRIQ
561 PRODUCT PROFILE (LATE STAGE): BINIMETINIB
574 PRODUCT PROFILE (LATE STAGE): ENCORAFENIB
588 PRODUCT PROFILE (LATE STAGE): LEFITOLIMOD
602 PRODUCT PROFILE (LATE STAGE): MASITINIB
616 PRODUCT PROFILE (LATE STAGE): NAPABUCASIN

LIST OF FIGURES
19 Figure 1: Colorectal cancer – current and future market dynamics analysis
20 Figure 2: Datamonitor Healthcare’s assessment summary of key marketed and pipeline drugs for colorectal cancer
27 Figure 3: Colorectal cancer sales across the US, Japan, and five major EU markets, by country, 2016–25
30 Figure 4: Second- and third-line pipeline colorectal cancer drug sales across the US, Japan, and five major EU markets, by brand, 2016–25
31 Figure 5: PD-1/PD-L1 drug sales in colorectal cancer across the US, Japan, and five major EU markets, by brand, 2016–25
33 Figure 6: Colorectal cancer sales across the US, Japan, and five major EU markets, by class, 2016–25
41 Figure 7: Patient-based forecast methodology for colorectal cancer
43 Figure 8: Price sources and calculations, by country
60 Figure 9: Avastin for colorectal cancer – SWOT analysis
61 Figure 10: Datamonitor Healthcare’s drug assessment summary of Avastin for colorectal cancer
62 Figure 11: Datamonitor Healthcare’s drug assessment summary of Avastin for colorectal cancer
64 Figure 12: Avastin sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
75 Figure 13: Cotellic for colorectal cancer – SWOT analysis
76 Figure 14: Datamonitor Healthcare’s drug assessment summary of Cotellic for colorectal cancer
77 Figure 15: Datamonitor Healthcare’s drug assessment summary of Cotellic for colorectal cancer
79 Figure 16: Cotellic sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
89 Figure 17: Cyramza for colorectal cancer – SWOT analysis
90 Figure 18: Datamonitor Healthcare’s drug assessment summary of Cyramza for colorectal cancer
91 Figure 19: Datamonitor Healthcare’s drug assessment summary of Cyramza for colorectal cancer
93 Figure 20: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
104 Figure 21: Erbitux for colorectal cancer – SWOT analysis
105 Figure 22: Datamonitor Healthcare’s drug assessment summary of Erbitux for colorectal cancer
106 Figure 23: Datamonitor Healthcare’s drug assessment summary of Erbitux for colorectal cancer
108 Figure 24: Erbitux sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
119 Figure 25: Keytruda for colorectal cancer – SWOT analysis
120 Figure 26: Datamonitor Healthcare’s drug assessment summary for Keytruda in colorectal cancer
121 Figure 27: Datamonitor Healthcare’s drug assessment summary for Keytruda in colorectal cancer
123 Figure 28: Keytruda sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
134 Figure 29: Lonsurf for colorectal cancer – SWOT analysis
135 Figure 30: Datamonitor Healthcare’s drug assessment summary of Lonsurf for colorectal cancer
136 Figure 31: Datamonitor Healthcare’s drug assessment summary of Lonsurf for colorectal cancer
138 Figure 32: Lonsurf sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
148 Figure 33: OncoVAX for colon cancer – SWOT analysis
149 Figure 34: Datamonitor Healthcare’s drug assessment summary of OncoVAX for colon cancer
150 Figure 35: Datamonitor Healthcare’s drug assessment summary of OncoVAX for colon cancer
152 Figure 36: OncoVAX sales for colon cancer in the US, 2016–25
159 Figure 37: Opdivo for colorectal cancer – SWOT analysis
160 Figure 38: Datamonitor Healthcare’s drug assessment summary of Opdivo for colorectal cancer
161 Figure 39: Datamonitor Healthcare’s drug assessment summary of Opdivo for colorectal cancer
163 Figure 40: Opdivo sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
174 Figure 41: Stivarga for colorectal cancer – SWOT analysis
175 Figure 42: Datamonitor Healthcare’s drug assessment summary of Stivarga for colorectal cancer
176 Figure 43: Datamonitor Healthcare’s drug assessment summary of Stivarga for colorectal cancer
178 Figure 44: Stivarga sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
187 Figure 45: TS-1 for colorectal cancer – SWOT analysis
188 Figure 46: Datamonitor Healthcare’s drug assessment summary of TS-1 in colorectal cancer
189 Figure 47: Datamonitor Healthcare’s drug assessment summary of TS-1 in colorectal cancer
191 Figure 48: TS-1 sales for colorectal cancer in Japan, 2016–25
199 Figure 49: Tecentriq for colorectal cancer – SWOT analysis
200 Figure 50: Datamonitor Healthcare’s drug assessment summary of Tecentriq for colorectal cancer
201 Figure 51: Datamonitor Healthcare’s drug assessment summary of Tecentriq for colorectal cancer
203 Figure 52: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
218 Figure 53: Vectibix for colorectal cancer – SWOT analysis
219 Figure 54: Datamonitor Healthcare’s drug assessment summary of Vectibix for colorectal cancer
220 Figure 55: Datamonitor Healthcare’s drug assessment summary of Vectibix for colorectal cancer
222 Figure 56: Vectibix sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
230 Figure 57: Zaltrap for colorectal cancer – SWOT analysis
231 Figure 58: Datamonitor Healthcare’s drug assessment summary of Zaltrap for colorectal cancer
232 Figure 59: Datamonitor Healthcare’s drug assessment summary of Zaltrap for colorectal cancer
234 Figure 60: Zaltrap sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
243 Figure 61: Binimetinib for colorectal cancer – SWOT analysis
244 Figure 62: Datamonitor Healthcare’s drug assessment summary for binimetinib in colorectal cancer
245 Figure 63: Datamonitor Healthcare’s drug assessment summary for binimetinib in colorectal cancer
247 Figure 64: Binimetinib sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
257 Figure 65: Lefitolimod for colorectal cancer – SWOT analysis
258 Figure 66: Datamonitor Healthcare’s drug assessment summary for lefitolimod in colorectal cancer
259 Figure 67: Datamonitor Healthcare’s drug assessment summary for lefitolimod in colorectal cancer
261 Figure 68: Lefitolimod sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
271 Figure 69: Masitinib for colorectal cancer – SWOT analysis
272 Figure 70: Datamonitor Healthcare’s drug assessment summary for masitinib in colorectal cancer
273 Figure 71: Datamonitor Healthcare’s drug assessment summary for masitinib in colorectal cancer
275 Figure 72: Masitinib sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
285 Figure 73: Napabucasin for colorectal cancer – SWOT analysis
286 Figure 74: Datamonitor Healthcare’s drug assessment summary for napabucasin in colorectal cancer
287 Figure 75: Datamonitor Healthcare’s drug assessment summary for napabucasin in colorectal cancer
289 Figure 76: Napabucasin sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
307 Figure 77: Distribution of colorectal cancer patients across the US, Japan, and five major EU markets, by stage (%)
312 Figure 78: Percentage of Stage I and Stage II colorectal cancer patients receiving each type of treatment, by country
314 Figure 79: Percentage of Stage III colorectal cancer patients receiving each type of treatment, by country
315 Figure 80: Percentage of Stage III colorectal cancer patients treated with surgery and systemic therapy who receive neoadjuvant or adjuvant therapy, by country
316 Figure 81: Top three regimens used in the adjuvant treatment of Stage III colorectal cancer patients, by country
317 Figure 82: Percentage of Stage IV colorectal cancer patients receiving each treatment type, by country
319 Figure 83: Top three regimens used in the first-line treatment of Stage IV colorectal cancer patients receiving systemic therapy without surgery, by country
321 Figure 84: Top three regimens used in the first-line maintenance treatment of Stage IV colorectal cancer patients, by country
322 Figure 85: Percentage of Stage IV colorectal cancer patients currently receiving each line of therapy, by country
323 Figure 86: Top three regimens used for second-line treatment of Stage IV colorectal cancer patients, by country
325 Figure 87: Top three regimens used for third-line treatment of Stage IV colorectal cancer patients, by country
326 Figure 88: Percentage of local relapse colorectal cancer patients receiving each treatment type, by country
327 Figure 89: Top three regimens used in the adjuvant treatment of local relapse colorectal cancer patients, by country
328 Figure 90: Percentage of distant relapse colorectal cancer patients receiving each treatment type, by country
329 Figure 91: Top three regimens used in the first-line treatment of distant relapse CRC patients receiving systemic therapy without surgery, by country
356 Figure 92: Trends in incident cases of colorectal cancer in the US, Japan, and five major EU markets, by country, 2017–37
377 Figure 93: Avastin for colorectal cancer – SWOT analysis
378 Figure 94: Datamonitor Healthcare’s drug assessment summary of Avastin for colorectal cancer
379 Figure 95: Datamonitor Healthcare’s drug assessment summary of Avastin for colorectal cancer
381 Figure 96: Avastin sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
392 Figure 97: Cyramza for colorectal cancer – SWOT analysis
393 Figure 98: Datamonitor Healthcare’s drug assessment summary of Cyramza for colorectal cancer
394 Figure 99: Datamonitor Healthcare’s drug assessment summary of Cyramza for colorectal cancer
396 Figure 100: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
407 Figure 101: Erbitux for colorectal cancer – SWOT analysis
408 Figure 102: Datamonitor Healthcare’s drug assessment summary of Erbitux for colorectal cancer
409 Figure 103: Datamonitor Healthcare’s drug assessment summary of Erbitux for colorectal cancer
411 Figure 104: Erbitux sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
422 Figure 105: Keytruda for colorectal cancer – SWOT analysis
423 Figure 106: Datamonitor Healthcare’s drug assessment summary for Keytruda in colorectal cancer
424 Figure 107: Datamonitor Healthcare’s drug assessment summary for Keytruda in colorectal cancer
426 Figure 108: Keytruda sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
437 Figure 109: Lonsurf for colorectal cancer – SWOT analysis
438 Figure 110: Datamonitor Healthcare’s drug assessment summary of Lonsurf for colorectal cancer
439 Figure 111: Datamonitor Healthcare’s drug assessment summary of Lonsurf for colorectal cancer
441 Figure 112: Lonsurf sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
451 Figure 113: Opdivo for colorectal cancer – SWOT analysis
452 Figure 114: Datamonitor Healthcare’s drug assessment summary of Opdivo for colorectal cancer
453 Figure 115: Datamonitor Healthcare’s drug assessment summary of Opdivo for colorectal cancer
455 Figure 116: Opdivo sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
466 Figure 117: Stivarga for colorectal cancer – SWOT analysis
467 Figure 118: Datamonitor Healthcare’s drug assessment summary of Stivarga for colorectal cancer
468 Figure 119: Datamonitor Healthcare’s drug assessment summary of Stivarga for colorectal cancer
470 Figure 120: Stivarga sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
479 Figure 121: TS-1 for colorectal cancer – SWOT analysis
480 Figure 122: Datamonitor Healthcare’s drug assessment summary of TS-1 in colorectal cancer
481 Figure 123: Datamonitor Healthcare’s drug assessment summary of TS-1 in colorectal cancer
483 Figure 124: TS-1 sales for colorectal cancer in Japan, 2016–25
496 Figure 125: Vectibix for colorectal cancer – SWOT analysis
497 Figure 126: Datamonitor Healthcare’s drug assessment summary of Vectibix for colorectal cancer
498 Figure 127: Datamonitor Healthcare’s drug assessment summary of Vectibix for colorectal cancer
500 Figure 128: Vectibix sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
508 Figure 129: Zaltrap for colorectal cancer – SWOT analysis
509 Figure 130: Datamonitor Healthcare’s drug assessment summary of Zaltrap for colorectal cancer
510 Figure 131: Datamonitor Healthcare’s drug assessment summary of Zaltrap for colorectal cancer
512 Figure 132: Zaltrap sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
527 Figure 133: Cotellic for colorectal cancer – SWOT analysis
528 Figure 134: Datamonitor Healthcare’s drug assessment summary of Cotellic for colorectal cancer
529 Figure 135: Datamonitor Healthcare’s drug assessment summary of Cotellic for colorectal cancer
531 Figure 136: Cotellic sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
541 Figure 137: OncoVAX for colon cancer – SWOT analysis
542 Figure 138: Datamonitor Healthcare’s drug assessment summary of OncoVAX for colon cancer
543 Figure 139: Datamonitor Healthcare’s drug assessment summary of OncoVAX for colon cancer
545 Figure 140: OncoVAX sales for colon cancer in the US, 2016–25
552 Figure 141: Tecentriq for colorectal cancer – SWOT analysis
553 Figure 142: Datamonitor Healthcare’s drug assessment summary of Tecentriq for colorectal cancer
554 Figure 143: Datamonitor Healthcare’s drug assessment summary of Tecentriq for colorectal cancer
556 Figure 144: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
565 Figure 145: Binimetinib for colorectal cancer – SWOT analysis
566 Figure 146: Datamonitor Healthcare’s drug assessment summary for binimetinib in colorectal cancer
567 Figure 147: Datamonitor Healthcare’s drug assessment summary for binimetinib in colorectal cancer
569 Figure 148: Binimetinib sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
579 Figure 149: Encorafenib for colorectal cancer – SWOT analysis
580 Figure 150: Datamonitor Healthcare’s drug assessment summary for encorafenib in colorectal cancer
581 Figure 151: Datamonitor Healthcare’s drug assessment summary for encorafenib in colorectal cancer
583 Figure 152: Encorafenib sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
593 Figure 153: Lefitolimod for colorectal cancer – SWOT analysis
594 Figure 154: Datamonitor Healthcare’s drug assessment summary for lefitolimod in colorectal cancer
595 Figure 155: Datamonitor Healthcare’s drug assessment summary for lefitolimod in colorectal cancer
597 Figure 156: Lefitolimod sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
607 Figure 157: Masitinib for colorectal cancer – SWOT analysis
608 Figure 158: Datamonitor Healthcare’s drug assessment summary for masitinib in colorectal cancer
609 Figure 159: Datamonitor Healthcare’s drug assessment summary for masitinib in colorectal cancer
611 Figure 160: Masitinib sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
621 Figure 161: Napabucasin for colorectal cancer – SWOT analysis
622 Figure 162: Datamonitor Healthcare’s drug assessment summary for napabucasin in colorectal cancer
623 Figure 163: Datamonitor Healthcare’s drug assessment summary for napabucasin in colorectal cancer
625 Figure 164: Napabucasin sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25

LIST OF TABLES
28 Table 1: Colorectal cancer sales across the US, Japan, and five major EU markets, by country ($m), 2016–25
32 Table 2: PD-1/PD-L1 colorectal cancer drug sales across the US, Japan, and five major EU markets, by brand ($m), 2016–25
34 Table 3: Colorectal cancer sales across the US, Japan, and five major EU markets, by brand and class ($m), 2016–25
38 Table 4: Summary of drug classes and molecules included in Datamonitor Healthcare’s colorectal cancer patient-based forecast
44 Table 5: Exchange rates used for calculating prices
46 Table 6: Medical oncologists and gastroenterologists surveyed for the colorectal cancer primary research study, 2016
54 Table 7: Avastin drug profile
55 Table 8: Overview of major approvals for Avastin in colorectal cancer
56 Table 9: Avastin Phase III data in colorectal cancer
65 Table 10: Avastin sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
67 Table 11: Patients treated with Avastin across the US, Japan, and five major EU markets, by country, 2016–25
71 Table 12: Cotellic drug profile
72 Table 13: Cotellic Phase III trial in colorectal cancer
74 Table 14: Cotellic early-phase data in colorectal cancer
80 Table 15: Cotellic sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
82 Table 16: Patients treated with Cotellic in the US and five major EU markets, by country, 2016–25
84 Table 17: Cyramza drug profile
86 Table 18: Cyramza Phase III data in colorectal cancer
88 Table 19: Cyramza Phase I trials in colorectal cancer
94 Table 20: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
96 Table 21: Patients treated with Cyramza across the US, Japan, and five major EU markets, by country, 2016–25
98 Table 22: Erbitux drug profile
99 Table 23: Overview of major approvals for Erbitux in colorectal cancer
101 Table 24: Erbitux Phase III data in colorectal cancer
103 Table 25: Erbitux Phase III data in colorectal cancer
109 Table 26: Erbitux sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
111 Table 27: Patients treated with Erbitux across the US, Japan, and five major EU markets, by country, 2016–25
115 Table 28: Keytruda drug profile
116 Table 29: Keytruda Phase III trial in colorectal cancer
118 Table 30: Keytruda early-phase data in colorectal cancer
124 Table 31: Keytruda sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
126 Table 32: Patients treated with Keytruda across the US, Japan, and five major EU markets, by country, 2016–25
130 Table 33: Lonsurf drug profile
131 Table 34: Lonsurf Phase III data in colorectal cancer
133 Table 35: Lonsurf Phase II trials in colorectal cancer
139 Table 36: Lonsurf sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
141 Table 37: Patients treated with Lonsurf across the US, Japan, and five major EU markets, by country, 2016–25
144 Table 38: OncoVAX drug profile
145 Table 39: OncoVAX Phase III trial in colon cancer
147 Table 40: OncoVAX Phase III data in colon cancer
152 Table 41: OncoVAX sales for colon cancer in the US ($m), 2016–25
153 Table 42: Patients treated with OncoVAX in the US, 2016–25
155 Table 43: Opdivo drug profile
156 Table 44: Opdivo pivotal trial data in colorectal cancer
158 Table 45: Opdivo early-phase trials in colorectal cancer
164 Table 46: Opdivo sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
166 Table 47: Patients treated with Opdivo across the US and five major EU markets, by country, 2016–25
169 Table 48: Stivarga drug profile
171 Table 49: Stivarga pivotal trial data in colorectal cancer
173 Table 50: Stivarga ongoing trials in colorectal cancer
179 Table 51: Stivarga sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
181 Table 52: Patients treated with Stivarga across the US, Japan, and five major EU markets, by country, 2016–25
184 Table 53: TS-1 drug profile
186 Table 54: TS-1 pivotal trial data in colorectal cancer
191 Table 55: TS-1 sales for colorectal cancer in Japan ($m), 2016–25
192 Table 56: Patients treated with TS-1 in Japan, 2016–25
195 Table 57: Tecentriq drug profile
196 Table 58: Tecentriq Phase III trial in colorectal cancer
198 Table 59: Tecentriq early-phase data in colorectal cancer
204 Table 60: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
206 Table 61: Patients treated with Tecentriq in the US and five major EU markets, by country, 2016–25
208 Table 62: Vectibix drug profile
210 Table 63: Overview of major approvals for Vectibix in colorectal cancer
211 Table 64: Vectibix pivotal trial data in colorectal cancer
217 Table 65: Vectibix early-phase data in colorectal cancer
223 Table 66: Vectibix sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
225 Table 67: Patients treated with Vectibix in the US, Japan, and five major EU markets, by country, 2016–25
227 Table 68: Zaltrap drug profile
229 Table 69: Zaltrap pivotal trial data in colorectal cancer
235 Table 70: Zaltrap sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
237 Table 71: Patients treated with Zaltrap in the US, Japan, and five major EU markets, by country, 2016–25
240 Table 72: Binimetinib drug profile
242 Table 73: Binimetinib Phase III data in colorectal cancer
248 Table 74: Binimetinib sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
250 Table 75: Patients treated with binimetinib in the US and five major EU markets, by country, 2016–25
253 Table 76: Lefitolimod drug profile
254 Table 77: Lefitolimod Phase III trial in colorectal cancer
256 Table 78: Lefitolimod Phase II data in colorectal cancer
262 Table 79: Lefitolimod sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
264 Table 80: Patients treated with lefitolimod across the US, Japan, and five major EU markets, by country, 2016–25
266 Table 81: Masitinib drug profile
268 Table 82: Masitinib Phase III trial in colorectal cancer
270 Table 83: Masitinib early-phase data in colorectal cancer
276 Table 84: Masitinib sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
278 Table 85: Patients treated with masitinib across the US and five major EU markets, by country, 2016–25
281 Table 86: Napabucasin drug profile
282 Table 87: Napabucasin Phase III trial in colorectal cancer
284 Table 88: Napabucasin Phase III data in colorectal cancer
290 Table 89: Napabucasin sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
292 Table 90: Patients treated with napabucasin across the US, Japan, and five major EU markets, by country, 2016–25
296 Table 91: Medical oncologists and gastroenterologists surveyed for the colorectal cancer primary research study, 2016
301 Table 92: Colorectal cancer five-year survival rates, by stage at diagnosis
306 Table 93: TNM classification, by stage at diagnosis
309 Table 94: Leading treatments for colorectal cancer
337 Table 95: ICD-10 codes for primary sites of colorectal cancer cases
338 Table 96: Cancer registry databases used as a source of colorectal cancer incidence data, by country
343 Table 97: Forecasting methodology for colorectal cancer incidence, by country, cancer site, gender, and age group
347 Table 98: Data sources used for stage distribution of colorectal cancer, by country
350 Table 99: Sources of survival data used to estimate colorectal cancer prevalence, by country
351 Table 100: Validation of forecast estimates against benchmark estimates
353 Table 101: Incident cases of colorectal cancer in the US, Japan, and five major EU markets, by country, 2017–37
363 Table 102: AJCC TNM staging classification
368 Table 103: Profiled key marketed drugs for colorectal cancer
371 Table 104: Avastin drug profile
372 Table 105: Overview of major approvals for Avastin in colorectal cancer
373 Table 106: Avastin Phase III data in colorectal cancer
382 Table 107: Avastin sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
384 Table 108: Patients treated with Avastin across the US, Japan, and five major EU markets, by country, 2016–25
387 Table 109: Cyramza drug profile
389 Table 110: Cyramza Phase III data in colorectal cancer
391 Table 111: Cyramza Phase I trials in colorectal cancer
397 Table 112: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
399 Table 113: Patients treated with Cyramza across the US, Japan, and five major EU markets, by country, 2016–25
401 Table 114: Erbitux drug profile
402 Table 115: Overview of major approvals for Erbitux in colorectal cancer
404 Table 116: Erbitux Phase III data in colorectal cancer
406 Table 117: Erbitux Phase III data in colorectal cancer
412 Table 118: Erbitux sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
414 Table 119: Patients treated with Erbitux across the US, Japan, and five major EU markets, by country, 2016–25
418 Table 120: Keytruda drug profile
419 Table 121: Keytruda Phase III trial in colorectal cancer
421 Table 122: Keytruda early-phase data in colorectal cancer
427 Table 123: Keytruda sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
429 Table 124: Patients treated with Keytruda across the US, Japan, and five major EU markets, by country, 2016–25
433 Table 125: Lonsurf drug profile
434 Table 126: Lonsurf Phase III data in colorectal cancer
436 Table 127: Lonsurf Phase II trials in colorectal cancer
442 Table 128: Lonsurf sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
444 Table 129: Patients treated with Lonsurf across the US, Japan, and five major EU markets, by country, 2016–25
447 Table 130: Opdivo drug profile
448 Table 131: Opdivo pivotal trial data in colorectal cancer
450 Table 132: Opdivo early-phase trials in colorectal cancer
456 Table 133: Opdivo sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
458 Table 134: Patients treated with Opdivo across the US and five major EU markets, by country, 2016–25
461 Table 135: Stivarga drug profile
463 Table 136: Stivarga pivotal trial data in colorectal cancer
465 Table 137: Stivarga ongoing trials in colorectal cancer
471 Table 138: Stivarga sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
473 Table 139: Patients treated with Stivarga across the US, Japan, and five major EU markets, by country, 2016–25
476 Table 140: TS-1 drug profile
478 Table 141: TS-1 pivotal trial data in colorectal cancer
483 Table 142: TS-1 sales for colorectal cancer in Japan ($m), 2016–25
484 Table 143: Patients treated with TS-1 in Japan, 2016–25
486 Table 144: Vectibix drug profile
488 Table 145: Overview of major approvals for Vectibix in colorectal cancer
489 Table 146: Vectibix pivotal trial data in colorectal cancer
495 Table 147: Vectibix early-phase data in colorectal cancer
501 Table 148: Vectibix sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
503 Table 149: Patients treated with Vectibix in the US, Japan, and five major EU markets, by country, 2016–25
505 Table 150: Zaltrap drug profile
507 Table 151: Zaltrap pivotal trial data in colorectal cancer
513 Table 152: Zaltrap sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
515 Table 153: Patients treated with Zaltrap in the US, Japan, and five major EU markets, by country, 2016–25
520 Table 154: Profiled pipeline products in development for colorectal cancer
523 Table 155: Cotellic drug profile
524 Table 156: Cotellic Phase III trial in colorectal cancer
526 Table 157: Cotellic early-phase data in colorectal cancer
532 Table 158: Cotellic sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
534 Table 159: Patients treated with Cotellic in the US and five major EU markets, by country, 2016–25
537 Table 160: OncoVAX drug profile
538 Table 161: OncoVAX Phase III trial in colon cancer
540 Table 162: OncoVAX Phase III data in colon cancer
545 Table 163: OncoVAX sales for colon cancer in the US ($m), 2016–25
546 Table 164: Patients treated with OncoVAX in the US, 2016–25
548 Table 165: Tecentriq drug profile
549 Table 166: Tecentriq Phase III trial in colorectal cancer
551 Table 167: Tecentriq early-phase data in colorectal cancer
557 Table 168: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
559 Table 169: Patients treated with Tecentriq in the US and five major EU markets, by country, 2016–25
562 Table 170: Binimetinib drug profile
564 Table 171: Binimetinib Phase III data in colorectal cancer
570 Table 172: Binimetinib sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
572 Table 173: Patients treated with binimetinib in the US and five major EU markets, by country, 2016–25
575 Table 174: Encorafenib drug profile
576 Table 175: Encorafenib Phase III data in colorectal cancer
578 Table 176: Encorafenib Phase II data in colorectal cancer
584 Table 177: Encorafenib sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
586 Table 178: Patients treated with encorafenib across the US and five major EU markets, by country, 2016–25
589 Table 179: Lefitolimod drug profile
590 Table 180: Lefitolimod Phase III trial in colorectal cancer
592 Table 181: Lefitolimod Phase II data in colorectal cancer
598 Table 182: Lefitolimod sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
600 Table 183: Patients treated with lefitolimod across the US, Japan, and five major EU markets, by country, 2016–25
602 Table 184: Masitinib drug profile
604 Table 185: Masitinib Phase III trial in colorectal cancer
606 Table 186: Masitinib early-phase data in colorectal cancer
612 Table 187: Masitinib sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
614 Table 188: Patients treated with masitinib across the US and five major EU markets, by country, 2016–25
617 Table 189: Napabucasin drug profile
618 Table 190: Napabucasin Phase III trial in colorectal cancer
620 Table 191: Napabucasin Phase III data in colorectal cancer
626 Table 192: Napabucasin sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
628 Table 193: Patients treated with napabucasin across the US, Japan, and five major EU markets, by country, 2016–25